I agree that while a little confusing as to how many and which patients are enrolled under emergency IND or under either the TNBC or basket trial, the most important thing for both the patients, CytoDyn and us investors is that enrollment is increasing. The lives that will hopefully be saved will speak for themselves regardless if in the actual trial or not. Even though the basket trial is only designed for 30 patients, I hope they enroll or inject all patients that pass the CCR5 screening and are able to make a difference to these individuals and their families. Everything else will work out how it supposed to given time.